Stockreport

MeiraGTx seeks UK approval after gene therapy restores sight in children born blind [Yahoo! Finance]

MeiraGTx Holdings plc - Ordinary Shares  (MGTX) 
PDF The AAV-AIPL1 therapy is designed to address severe sight impairment caused by mutations in the AIPL1 gene. This condition is a form of retinal dystrophy that leads to [Read more]